Raysteeds Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -19.82%
- Profit Growth 99.38%
- Ebitda 108.01%
- Net Worth -5.01%
- Total Assets -12.19%
About Raysteeds Drugs
Raysteeds Drugs Private Limited (RDPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 13 June 2017 (Seven years and eight months 12 days old ). Its registered office is in Dehradun, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satyendra Srivastava and Prakhar Srivastava serve as directors at the Company.
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999UR2017PTC007885
- Company No.
007885
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Raysteeds Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyendra Srivastava  | Director | 13-Jun-2017 | Current |
| Prakhar Srivastava | Director | 13-Jun-2017 | Current |
Financial Performance of Raysteeds Drugs.
Raysteeds Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.82% decrease. The company also saw a substantial improvement in profitability, with a 99.38% increase in profit. The company's net worth dipped by a decrease of 5.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raysteeds Drugs?
Unlock access to Raysteeds Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Raysteeds Energy Private LimitedSatyendra Srivastava and Prakhar Srivastava are mutual person
Raysteeds Infotech Private LimitedPrakhar Srivastava is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raysteeds Drugs?
Unlock and access historical data on people associated with Raysteeds Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raysteeds Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raysteeds Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.